# A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

> **NCT05630885** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 110 (actual)

## Conditions studied

- HIV-1-infection
- Elevated Cardiovascular Risk

## Interventions

- **DRUG:** CVC 150 mg
- **DRUG:** CVC 300 mg
- **OTHER:** Placebo for CVC 150 mg
- **OTHER:** Placebo for CVC 300 mg

## Key facts

- **NCT ID:** NCT05630885
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-30
- **Primary completion:** 2024-06-19
- **Final completion:** 2024-06-19
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630885, "A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05630885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*